49
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inhibition and induction of CYP enzymes in humans: an update

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies and toxic compounds in the environment. The inhibition and induction of CYPs are major mechanisms causing pharmacokinetic drug–drug interactions. This review presents a comprehensive update on the inhibitors and inducers of the specific CYP enzymes in humans. The focus is on the more recent human in vitro and in vivo findings since the publication of our previous review on this topic in 2008. In addition to the general presentation of inhibitory drugs and inducers of human CYP enzymes by drugs, herbal remedies, and toxic compounds, an in-depth view on tyrosine-kinase inhibitors and antiretroviral HIV medications as victims and perpetrators of drug–drug interactions is provided as examples of the current trends in the field. Also, a concise overview of the mechanisms of CYP induction is presented to aid the understanding of the induction phenomena.

          Related collections

          Most cited references548

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

          Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging to the CYP1, 2, and 3 families, are responsible for the biotransformation of most foreign substances including 70-80% of all drugs in clinical use. The highest expressed forms in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2, while 2A6, 2D6, 2B6, 2C19 and 3A5 are less abundant and CYPs 2J2, 1A1, and 1B1 are mainly expressed extrahepatically. Expression of each CYP is influenced by a unique combination of mechanisms and factors including genetic polymorphisms, induction by xenobiotics, regulation by cytokines, hormones and during disease states, as well as sex, age, and others. Multiallelic genetic polymorphisms, which strongly depend on ethnicity, play a major role for the function of CYPs 2D6, 2C19, 2C9, 2B6, 3A5 and 2A6, and lead to distinct pharmacogenetic phenotypes termed as poor, intermediate, extensive, and ultrarapid metabolizers. For these CYPs, the evidence for clinical significance regarding adverse drug reactions (ADRs), drug efficacy and dose requirement is rapidly growing. Polymorphisms in CYPs 1A1, 1A2, 2C8, 2E1, 2J2, and 3A4 are generally less predictive, but new data on CYP3A4 show that predictive variants exist and that additional variants in regulatory genes or in NADPH:cytochrome P450 oxidoreductase (POR) can have an influence. Here we review the recent progress on drug metabolism activity profiles, interindividual variability and regulation of expression, and the functional and clinical impact of genetic variation in drug metabolizing P450s. Copyright © 2013 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

            The transcription factor NF-E2 p45-related factor 2 (NRF2; encoded by NFE2L2) and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 (KEAP1), are critical in the maintenance of redox, metabolic and protein homeostasis, as well as the regulation of inflammation. Thus, NRF2 activation provides cytoprotection against numerous pathologies including chronic diseases of the lung and liver; autoimmune, neurodegenerative and metabolic disorders; and cancer initiation. One NRF2 activator has received clinical approval and several electrophilic modifiers of the cysteine-based sensor KEAP1 and inhibitors of its interaction with NRF2 are now in clinical development. However, challenges regarding target specificity, pharmacodynamic properties, efficacy and safety remain.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease

                Bookmark

                Author and article information

                Contributors
                olavi.pelkonen@oulu.fi
                Journal
                Arch Toxicol
                Arch Toxicol
                Archives of Toxicology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0340-5761
                1432-0738
                27 October 2020
                27 October 2020
                2020
                : 94
                : 11
                : 3671-3722
                Affiliations
                [1 ]GRID grid.10858.34, ISNI 0000 0001 0941 4873, Research Unit of Biomedicine, Pharmacology and Toxicology, , University of Oulu, ; POB 5000, 90014 Oulu, Finland
                [2 ]GRID grid.10858.34, ISNI 0000 0001 0941 4873, Biocenter Oulu, , University of Oulu, ; Oulu, Finland
                [3 ]GRID grid.10858.34, ISNI 0000 0001 0941 4873, Medical Research Center Oulu, , University of Oulu and Oulu University Hospital, ; Oulu, Finland
                [4 ]GRID grid.10858.34, ISNI 0000 0001 0941 4873, Research Unit of Internal Medicine, Medical Research Center Oulu, , University of Oulu and Oulu University Hospital, ; Oulu, Finland
                [5 ]GRID grid.10858.34, ISNI 0000 0001 0941 4873, Administration Center, Medical Research Center Oulu, , University of Oulu and Oulu University Hospital, ; Oulu, Finland
                Author information
                http://orcid.org/0000-0001-5048-4363
                Article
                2936
                10.1007/s00204-020-02936-7
                7603454
                33111191
                304e15e5-bdcc-4e41-b3de-918a3a1d9814
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 3 September 2020
                : 12 October 2020
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100002341, Academy of Finland;
                Award ID: 286743
                Award ID: 323706
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100008723, Suomen Lääketieteen Säätiö;
                Funded by: FundRef http://dx.doi.org/10.13039/501100005633, Sydäntutkimussäätiö;
                Funded by: FundRef http://dx.doi.org/10.13039/100011935, Pohjois-Suomen Terveydenhuollon Tukisäätiö;
                Funded by: FundRef http://dx.doi.org/10.13039/501100013500, Diabetestutkimussäätiö;
                Funded by: University of Oulu including Oulu University Hospital
                Categories
                Review Article
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2020

                Toxicology
                cytochrome p450,inhibition,induction,drug–drug interaction,herbal remedies,environmental toxicants

                Comments

                Comment on this article